Picking up the pieces

INITIUM top-line readout a punch in the gut. FOCUS is last hope. Valuation overhaul, HOLD (Buy), TP NOK 7 (180).

INITIUM fails

Taking immunotherapy to the next level

Cancer vaccine+CPI combo the next step in immunotherapy. Upcoming data points will be pivotal for the stock. Initiate with a BUY and TP of NOK 180.

Terminating coverage

Q3 report: advancing as planned

NIPU data at ESMO '23

How good is the good news?

NIPU study was likely good news. We want to see the full data before changing estimates. Full presentation at ESMO on Saturday, 21 Oct.

NIPU shows OS benefit

Ph 1 UV1-103; 4-years OS time

UV1 gets ODD in mesothelioma

NIPU data to be presented at ESMO'23

Q2 report: new timelines for INITIUM

UV1-pembro keep showing positives

INITIUM will tell

NIPU trial misses primary outcome. Despite negative cross-readout, however, there is still hope for INITIUM. New TP of NOK 100 (180).

Q1 report: NIPU readout soon

INITIUM readout update